• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Revvity Board Declares Quarterly Dividend

    10/24/24 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025.

    About Revvity

    At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

    With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

    Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241024806358/en/

    Get the next $RVTY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Revvity upgraded by UBS with a new price target

      UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

      5/1/25 7:42:49 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity downgraded by Bernstein with a new price target

      Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

      1/10/25 8:41:17 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity upgraded by BofA Securities with a new price target

      BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

      12/13/24 8:43:02 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials